Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

MARLOWE PLC Director's Dealing 2019

Jun 19, 2019

7777_dirs_2019-06-19_7c7f2f6f-0874-4f37-821a-c21a8fe618fa.html

Director's Dealing

Open in viewer

Opens in your device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 8039C

Marlowe PLC

19 June 2019

19 June 2019

Marlowe plc

Grant of Share Options

Marlowe plc ("Marlowe" or the "Group"), the specialist services group focused on developing companies which assure safety and regulatory compliance, announces that the Group has today granted share options over a total of 134,297 ordinary shares of 50 pence each in Marlowe (the "New Share Options").

The New Share Options have been awarded pursuant to the Group's Long Term Incentive Plan 2019, to drive and reward the achievement of the Group's longer-term objectives and to support retention. 92,975 of the New Share Options have been granted to Alex Dacre, Chief Executive, and 41,322 of the New Share Options have been granted to Mark Adams, Group Finance Director. The New Share Options will vest, in whole or in part, on 1 April 2022 (or upon a change of control) subject to the following performance conditions having been met over the preceding three-year period:

Compound Annual

Total Shareholder Return
Vesting
Less than 5% 0%
More than 15% 100%
Between 5% and 15% 0%-100% on a straight-line basis

Unless special circumstances apply, the New Share Options will normally lapse immediately on cessation of employment. Upon vesting, the New Share Options will be exercisable at a price of 50 pence per ordinary at any time prior to expiry on 31 March 2029.

The notifications below, made in accordance with the requirements of the EU Market Abuse Regulation, provide further details.

For further information:

Marlowe plc www.marloweplc.com
Alex Dacre, Chief Executive Tel: +44 (0) 203 841 6194
Mark Adams, Group Finance Director [email protected]
Cenkos Securities plc (Nominated Adviser & Joint Broker)
Nicholas Wells Tel: +44 (0)20 7397 8900
Ben Jeynes
Harry Hargreaves
Joh. Berenberg, Gossler & Co. KG, London Branch (Joint Broker)
Ben Wright Tel: +44 (0)20 3207 7800
Mark Whitmore
FTI Consulting
Nick Hasell Tel: +44 (0)20 3727 1340
Alex Le May

About Marlowe plc

Marlowe is a UK leader in specialist services which assure the safety and regulatory compliance of commercial properties, whilst managing risk for businesses across the country. The Group was formed to create sustainable shareholder value through the acquisition and development of businesses that provide regulated inspection, testing and compliance services. It is focused on health & safety, fire safety, security, water safety, water treatment, air quality and environmental services - all of which are vital to the wellbeing of its customers operations and are invariably governed by regulation. Marlowe currently provides services to over 10% of Britain's commercial properties and is increasingly attractive to customers who require a single outsourced, nationwide, provider of a comprehensive range of regulated safety services. Our customers can be found in most office complexes, high streets & leisure facilities, manufacturing plants and industrial estates, and include SMEs, local authorities, facilities management providers, multi-site NHS trusts and FTSE 100 companies.

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

1 Details of the person discharging managerial responsibilities / person closely associated
a) Name Alex Dacre
2 Reason for the notification
a) Position/status Chief Executive
b) Initial notification/Amendment Initial Notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name Marlowe plc
b) LEI 213800ZWSR4SBOM6B608
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument Ordinary shares of 50 pence each
Identification code GB00BD8SLV43
b) Nature of the transaction Grant of new options over ordinary shares
c) Price(s) and volumes(s) Price(s) Volume(s)
Exercise price - £0.50 per option 92,975
d) Aggregated information N/A single transaction
Aggregated volume N/A single transaction
Price N/A single transaction
e) Date of the transaction 19 June 2019
f) Place of the transaction Outside of a trading venue (XOFF)
1 Details of the person discharging managerial responsibilities / person closely associated
a) Name Mark Adams
2 Reason for the notification
a) Position/status Finance Director
b) Initial notification/Amendment Initial Notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name Marlowe plc
b) LEI 213800ZWSR4SBOM6B608
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument Ordinary shares of 50 pence each
Identification code GB00BD8SLV43
b) Nature of the transaction Grant of new options over ordinary shares
c) Price(s) and volumes(s) Price(s) Volume(s)
Exercise price - £0.50 per option 41,322
d) Aggregated information N/A single transaction
Aggregated volume N/A single transaction
Price N/A single transaction
e) Date of the transaction 19 June 2019
f) Place of the transaction Outside of a trading venue (XOFF)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

DSHLLFVSRSIALIA